drugset / Trial / NCT05256446

AMG 701 Expanded Access Program

NCT05256446

Expanded access No longer available Amgen

Summary

Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background pavurutamab Protein / enzyme biologic

Indications

No indication recorded.